In order to improve the survival rates and decrease progression of pancreatic advanced
cancer, this study aims to evaluate the first line treatment approved for this disease
(gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of
the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4
Pancreatic cancer is one of the leading neoplasms in the world in terms of mortality, with
very low survival rates mainly due to its rapid progression and diagnosis in advanced stages,
which makes its treatment extremely difficult.
Gemcitabine plus nab-paclitaxel is currently considered the first-line standard treatment for
advanced pancreatic cancer due to this superiority against other treatments.
In order to find an alternative to improve survival of advanced pancreatic cancer, this study
aims to evaluate the efficacy with first-line treatment in combination of two experimental
drugs, a Hedgehog pathway inhibitor (NLM-001) and a CTLA-4 blocker (zalifrelimab) in
previously untreated patients with advanced pancreatic cancer.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.